Home > Rheumatology > EULAR 2019 > Miscellaneous > Interstitial Lung Disease in Rheumatic Diseases and Systemic Sclerosis

Interstitial Lung Disease in Rheumatic Diseases and Systemic Sclerosis

Presented By
Dr Jan Grutters, University Medical Center Utrecht, the Netherlands
Conference
EULAR 2019
Trial
SENSCIS, INPULSIS, SLS-2

Interstitial lung disease (ILD) and connective tissue disease (CTD) are complicated diseases that require a systematic diagnosis and clinical expertise. Anti-inflammatory therapy is currently the only strategy that can improve lung function in CTD as shown in the scleroderma lung (SLS-2) study. Anti-fibrotic drugs appear useful as shown by the SENSCIS trial, although clinical implementation will be challenging. “We are awaiting data on anti-fibrotic drugs in other ILD/CTD. ILD requires teamwork and multidisciplinary discussion among rheumatologists, clinical immunologists, and pulmonologists with interest in ILD. This is strongly recommended,” concluded Dr Jan Grutters (University Medical Center Utrecht, the Netherlands).

“ILD can be considered as a large group of rare to ultra-rare molecular lung diseases. Over 150 diagnoses can be categorised in this group, and the underlying causes are mostly unknown,” he explained, before giving an overview of the ILD ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on